title: Biomarkers of psychiatric diseases: current status and future prospects.
abstract: Abnormal behavior and disturbed cognition, often assumed to represent psychiatric illness, may actually result from some form of occult organic brain disease that can be detected by means of one or more biomarkers. This truth was discovered more than a century ago by Aloysius Alzheimer, a German psychiatrist and neuropathologist. As a psychiatrist, he described the behavioral manifestations of "senile dementia" in a 51-year-old female; as a neuropathologist, he was the first to recognize the significance of the senile plaques and neurofibrillary tangles found in her brain after her death at age 55 years. It was Alzheimer who made the connection between these "biomarkers" and the symptoms of the increasingly prevalent disease that now bears his name. In recent years, the search for psychiatry-relevant biomarkers of major depression, schizophrenia, bipolar disease, and other important psychiatric/neuropsychiatric disorders has intensified. Biomarkers in psychiatry and neuropsychiatry have the potential of clarifying the etiology of an ambiguous clinical presentation-making it possible, for example, to detect underlying differences between psychological maladies that have confusingly similar symptoms. In addition, attempts are now being made to classify mental disorders on the basis of biomarkers. Biomarkers may also disclose the presence of a previously unsuspected physical explanation for behavior(s) originally presumed to be "psychiatric" in origin. Although clinically usable biomarkers in the diagnosis and treatment of mental illness await validation, candidate genomic biomarkers and protein profiling of candidate biomarkers in psychiatry are rapidly gaining ground as areas of interest, with considerable future potential. This review considers biomarker-related issues germane to psychiatry and neuropsychiatry in the context of new data that can be used to tailor therapies to the individual psychiatric patient.
authors.affiliation: Thomas Jefferson University, Philadelphia, PA 19107. Electronic address: madhu.kalia@jefferson.edu.
authors.forename: Madhu
authors.initials: M
authors.lastname: Kalia
authors.affiliation: Brazilian Brain Institute, 22461-210 Rio de Janeiro, Brazil.
authors.forename: Jorge
authors.initials: J
authors.lastname: Costa E Silva
mesh_terms: D000123:Acetyltransferases / Q000097:blood; D000544:Alzheimer Disease / Q000175:diagnosis / Q000266:history; D015415:Biomarkers; D001714:Bipolar Disorder / Q000175:diagnosis; D001921:Brain / Q000473:pathology*; D019208:Brain-Derived Neurotrophic Factor / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D016207:Cytokines / Q000097:blood; D003865:Major Depressive Disorder / Q000175:diagnosis; D004298:Dopamine / Q000378:metabolism; D049673:History, 20th Century; D006801:Humans; D028421:Isoprostanes / Q000097:blood; D008315:Malondialdehyde / Q000097:blood; D001523:Mental Disorders / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D019964:Mood Disorders / Q000175:diagnosis* / Q000628:therapy; D019798:Neopterin / Q000097:blood; D016874:Neurofibrillary Tangles; D064568:S100 Calcium Binding Protein beta Subunit / Q000097:blood; D012559:Schizophrenia / Q000175:diagnosis* / Q000628:therapy*; D059020:Suicidal Ideation; D005680:gamma-Aminobutyric Acid / Q000378:metabolism; D000099228:Diamine N-Acetyltransferase
chemical_list: D000123:Acetyltransferases; D015415:Biomarkers; D019208:Brain-Derived Neurotrophic Factor; D002097:C-Reactive Protein; D016207:Cytokines; D004298:Dopamine; D028421:Isoprostanes; D008315:Malondialdehyde; D019798:Neopterin; D064568:S100 Calcium Binding Protein beta Subunit; D005680:gamma-Aminobutyric Acid; D000099228:Diamine N-Acetyltransferase; C579160:S100B protein, human; C579455:BDNF protein, human
keywords: Bipolar disorder; Depression; Schizophrenia; Suicidality